

AGM Presentation

Next-generation exosome diagnostics and therapeutics

25 November 2026

INOVIQ

ASX: IIQ

Disclaimer

This presentation has been prepared by INOVIQ Limited ("INOVIQ" or the "Company") based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company's own information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.

This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including INOVIQ or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of INOVIQ cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.

AGM| Agenda



1. Business of Meeting
   - Chairmans Opening
   - Introductions
   - Resolutions
2. AGM Presentation
3. Questions
4. Voting Closure
5. Close of Meeting

INOVIQ

Board and Management| Corporate, scientific, clinical & commercial leadership

BOARD



Peter Gunzburg
Executive Chairman

Experienced public company director, stockbroker and investor.

Currently Non-Executive Chairman of ASX listed Metals X Limited and non-executive director of London Stock Exchange listed First Tin Plc.

Previously Director of the Australian Stock Exchange Ltd, Eyres Reed Ltd, CIBC World Markets Australia Ltd and several public companies.



MAX JOHNSTON
Non-Executive Director

Healthcare industry director and international business leader with extensive experience across medtech, pharmaceuticals, consumer healthcare and consumer goods.

Previously President and CEO of Johnson & Johnson Pacific, Chairman of AusCann Ltd, NED of PolyNovo Ltd, Medical Developments International Ltd, Tissue Repair Ltd, Neurotech International and CannPal Animal Therapeutics Ltd.



PHILIP POWELL
Non-Executive Director

Healthcare industry director and chartered accountant with extensive investment banking experience specialising in capital raisings, IPOs, mergers and acquisitions and other transactions across pharma, food and agriculture.

Previously at OAMPS Ltd and Arthur Andersen, and NED at RMA Global Ltd, Polynovo Ltd and Medical Developments International Ltd.



Andrew Chapman
Non-Executive Director

Founder of Merchant Funds Management and has over 25 years' experience in the financial services industry.

Financial markets expertise advising many biotech companies on capital raisings and financial markets strategy and execution.

Currently a Non-Executive Director of Argent BioPharma Ltd (ASX: RGT) and Neurotech International Ltd (ASX: NTI) and Chairman of Cycliq Group Ltd (ASX: CYQ).

MANAGEMENT



MARK EDWARDS BAcc CA
CFO & Company Secretary

Experienced finance executive with expertise in financial leadership and management, corporate governance, investor relations and corporate transactions.

Previous senior roles in ASX listed pharmaceutical, medical device and healthcare companies, including Medical Developments International (ASX:MVP) and Cogstate (ASX:CGS).



DR REBECCA LIM PhD
Chief Scientific Officer

Internationally recognised biotechnology executive with over 20 years' experience in translational research, clinical development and regulatory pathways for cell and gene therapies, regenerative medicine, and extracellular vesicle (EV) technologies.

She has led advanced therapy programs from preclinical stages to IND clearance and GMP manufacturing, with senior roles at CTMC (Resilience & MD Anderson JV), Prescient Therapeutics (ASX:PTX), Monash University and Hudson Institute to drive innovation in cell and exosome therapies.



EMMA BALL PhD MBA GAICD
Chief Commercial Officer

Experienced biotechnology commercialisation executive with expertise in business development, licensing, and strategic partnerships across therapeutics, vaccines and diagnostics.

Previous senior business development/licensing roles in multinational biotechnology companies Illumina Inc (NASDAQ:ILMN), CSL Behring / CSL Ltd (ASX:CSL) and operational roles in Australian biotechnology companies including Prima Biomed, now Immutep (ASX:IMM).

Advisors| Leading clinical researchers, oncologists and experts

CLINICAL



PROF MILES PRINCE
AM MBBS (Hons) MD FRACP FRCPA AFRCMA AFRACD FAHMS
Clinical Haematologist & Oncologist

Leading Clinical Haematologist and Oncologist and Professor at both Melbourne and Monash universities. He is an NHMRC Investigator Fellow and has been principal investigator of over 100 clinical trials including targeted therapeutics (CAR-T therapy) for haematological conditions and cancers.



PROF PHIL DARCY
PhD FAHMS
Immunotherapy expert

Co-leader of the Cancer Immunology program, Group Leader of the Cancer Immunotherapy Laboratory at the Peter MacCallum Cancer Centre and NHMRC Principal Research Fellow, focusing on novel T cell-based immunotherapy approaches for cancer in preclinical mouse models and clinical translation.



PROF CARLOS SALOMON
BBiochem MClinMed PhD
Exosome expert

Director of the University of Queensland Centre for Extracellular Vesicle Nanomedicine, Head of the Translational Extracellular Vesicles in Obstetrics and GynaeOncology Group and NHMRC Investigator Fellow, specialising in exosome biology and its clinical translation to diagnostics and therapeutics for ovarian cancer and obstetrical syndromes.



DR JAMES MCCRACKEN
MBBS FRACP DipPsych MPHA
Medical Oncologist

Leading Medical Oncologist specialising in breast cancer treatment at Epworth Healthcare and the Peter MacCallum Cancer Centre. His research interests include the field of liquid biopsies for cancer to personalise treatment and minimise toxicity.

ADVISORS



PROF GREG RICE
PhD MHA
Founding Scientist & Advisor

Globally recognised, award-winning scientist with over 35 years' experience and a successful track record in oncology research, exosome science, biomarker discovery, and diagnostics development.

Previous leadership roles in academia and industry including at The University of Queensland Centre for Clinical Research, Baker Heart Institute, University of Melbourne, Monash University and HealthLinx (ASX:HTX).



PROF AMANDA BARNARD
AM BSc(Hons) PhD DSc FAIP FRSC FACS
Machine Learning & AI

A strategic leader and one of Australia's most highly awarded computational scientists, whose research in high performance supercomputing, applied machine learning and artificial intelligence spans nanoscience, materials, engineering, chemistry and health. With more than 20 years' experience, she is deeply engaged in international science diplomacy and research governance, and in 2022 was appointed a Member of the Order of Australia for significant service to science and the community.



DR JONATHAN SEAH
MB BCh BAO MBA
China / SE Asia Advisor

Senior healthcare investor with over 30 years' experience across clinical medicine, investment banking and hospital management. Currently a venture partner, adviser and director of Sanara Capital, Sabai Health AI and LifeClinic HK. Former CEO of IHH Healthcare (China Division) and Chairman & CEO of Tian An Medicare, with earlier roles at Merrill Lynch Investment Banking, Biotronik, and a physician at Singapore National University Hospital. Holds a medical degree from the Royal College of Surgeons and an MBA from Harvard Business School.

CSO Presentation



INOVIQ

Exosomes| Platform for advanced diagnostics & therapeutics

Extracellular vesicles (EVs) are tiny packages released by all cells – carry RNA, proteins and lipids that act as the body's messaging system



DIAGNOSTICS

Early, accurate detection from a simple liquid biopsy

EV signals provide an early window into disease status



PRECISION MEDICINE

Real-time insight across the cancer care continuum

Tumour-derived EVs track response and resistance



THERAPEUTICS

Targeted delivery to where it matters

Engineered EVs deliver payloads to kill cancer cells

INOVIQ EV technologies enable applications from biomarker discovery to advanced diagnostics and therapeutics

INOVIQ

EXO-OC™: From blood draw to clinically actionable result



1 Blood sample
A simple, minimally invasive blood draw

2 Selective exosome capture
Enriches for tumour-derived exosomes and removes unwanted vesicles (e.g. platelets)

3 Biomarker analysis
Measures a defined panel of exosomal biomarkers (e.g. miRNA and/or protein)

4 Computation (algorithm)
Integrates biomarker signals using a validated machine learning model to classify the result

5 Clinical result
A clear, actionable result to inform clinical decision-making

How it works

Exosome
Nanovesicle that carries cancer signals

Biomarkers
Molecular signals (e.g. miRNA, protein) that reflect cancer

Machine learning
Identifies cancer-specific patterns from multiple biomarkers

Clinical insight
A simple result to support earlier detection and patient management

The benefits

- Minimally invasive
- Tumour-focused
- High accuracy and clinical utility
- Supports high-risk surveillance and earlier detection

INOVIQ

Optimisation of EXO-OC™

Refining the biomarker algorithm with independent rigour, alongside a defined US laboratory validation pathway

INOVIQ DEVELOPMENT

Refine the test

- Optimise sample handling and exosome capture
- Refine biomarkers and the ML-based algorithm

EXTERNAL EXPERTISE

Apply independent rigour

- Independent technical expertise to support EXO-OC optimisation
- Independent verification and robust evaluation as development progresses

TEST VALIDATION

Validate with Sonic

- Transfer EXO-OC into Sonic's US laboratory
- Optimisation and laboratory validation at a CLIA-certified site

Successful validation → **LDT / regulatory readiness** → **US LDT**

INOVIQ

Timeline and milestones for EXO-OC™



- INOVIQ Ltd internal activities (firm)
- INOVIQ Ltd internal activities (contingent on specimen acquisition)
- Qualified biospecimen repositories
- Sonic Healthcare USA

INOVIQ

Therapeutics program remains on track

Screening candidate therapies to disrupt cancer survival while supporting reliable production



IDENTIFY

Find biological pathways critical to TNBC cancer cell survival



TEST

Evaluate for cancer-cell activity and producer-cell compatibility



ADVANCE

Progress selected candidates toward engineered cell-line development

Two promising payload candidates identified for further development for cell line engineering

INOVIQ

CAR-exosome development on track for progression to clinical stage

Key program components selected to support progression toward clinical development

Clinical path



Dual targets selected

Determines which cells take up the engineered EVs



Candidate payloads selected

Determines biological effect



Producer cell line selected

Determines how the EVs will be manufactured



Progress to engineering

Integrating the selected design

Growing momentum across target selection, payload selection and producer-cell selection

INOVIQ

Timeline and milestones for CAR-exosome program



Progress on SubB2M/Neu5Gc

Established evidence

Breast cancer study

Retrospective case-control data showed promising differentiation against a leading comparator.

Design improvements

Performance and implementation

Design improvements of detection reagent to enable scalable manufacturing of test.

Focused development

Evidence-led progression

Further optimisation, verification and platform compatibility underway with external CRO. Results expected Q1 2027.



INOVIQ

Contacts



Peter Gunzburg
Executive Chair
e. peter.gunzburg@gmail.com



Mark Edwards BAcc CA
CFO & Company Secretary
e. medwards@inoviq.com



Dr Rebecca Lim PhD
Chief Scientific Officer
e. rlim@inoviq.com



Dr Emma Ball PhD MBA GAICD
Chief Commercial Officer
e. eball@inoviq.com

INOVIQ Ltd, 23 Normanby Road, Notting Hill, VIC 3168 Australia
p. +61 3 9548 7586 | e. info@inoviq.com | w. www.inoviq.com